Epstein Secrets

M.D. F.A.C.C. Associate Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai Director, Clinical Cardiology Mount Sinai West Mount Sinai Heart 425 West 59th Street 9th Floor New York, NY 10019 212-752-2700 212-731-3730 Fax 212-376-3190 Cell 917-922-7391 dictated and sent from a

uction with Evolocumab Reply-To: Cardiology Alert <I Email not displaying correctyNiaw it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study. presented at the 2

M.D. F.A.C.C. Associate Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai Director, Clinical Cardiology Mount Sinai West Mount Sinai Heart 425 West 59th Street 9th Floor New York, NY 10019 212-752-2700 212-731-3730 Fax 212-376-3190 Cell 917-922-7391 dictated and sent from a

cumab Reply-To: Cardiology Alert < EFTA00447987 Entail not displaying coirectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2

M.D. F.A.C.C. Associate Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai Director, Clinical Cardiology Mount Sinai West Mount Sinai Heart 425 West 59th Street 9th Floor New York, NY 10019 212-752-2700 212-731-3730 Fax 212-376-3190 Cell 917-922-7391 dictated and sent from a

eduction with Evolocumab Reply-To: Cardiology Alert E— ail not displaying conectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2